My recent visit to Zimbabwe

 The journey was well planned and it took us less than 10 hours to reach our destination from Pretoria South Africa to Mvuma central Zimbabwe.  A lot of construction is happening on the roads. Harare to Masvingo Highway is complete and the remaining part which was left between Beitbridge and Masvingo is being completed.  Surely by December it should be done. Though there is a lot of money being miss used, there are elements of success. Harare to Beitbridge road was a death trap, the road had so many potholes, had no shoulder no fencing to protect  animals from entering the road and some parts even worn out that left it narrow in a way that two trucks cannot pass without one having to go out of the road.  Those improvements form part of the new Government's transformation policy. There is job creation and slowly improving the standards which has been declining for more that 20 to 30 years. Surely Rome was not built over night. At the border you can see significan...

Israeli study finds 94% drop in symptomatic COVID-19 cases with Pfizer vaccine By Reuters• 14 February 2021 A Pfizer vaccine will be rolled out to every state i

 

JERUSALEM, Feb 14 (Reuters) - Israel's largest healthcare provider on Sunday reported a 94% drop in symptomatic COVID-19 infections among 600,000 people who received two doses of the Pfizer's vaccine in the country's biggest study to date.

Health maintenance organization (HMO) Clalit, which covers more than half of all Israelis, said the same group was also 92% less likely to develop severe illness from the virus.

The comparison was against a group of the same size, with matching medical histories, who had not received the vaccine.

“It shows unequivocally that Pfizer’s coronavirus vaccine is extremely effective in the real world a week after the second dose, just as it was found to be in the clinical study,” said Ran Balicer, Clalit’s chief innovation officer.

He added that the data indicates the Pfizer vaccine, which was developed in partnership with Germany’s BioNTech, is even more effective two weeks or more after the second shot.

Researchers at the Weizmann Institute of Science, who have been tabulating national data, said on Sunday that a sharp decline in hospitalisation and serious illness identified earlier among the first age group to be vaccinated – aged 60 or older – was seen for the first time in those aged 55 and older.

Hospitalisations and serious illness were still rising in younger groups who began vaccinations weeks later.

Israel has been conducting a rapid vaccine rollout and its database offers insights into vaccine effectiveness and at what point countries might attain herd immunity. (Reporting by Ari Rabinovitch and Maayan Lubell Editing by David Goodman)


Comments

Popular posts from this blog

MultiChoice’s BEE scheme trying to find 22 000 shareholders who are missing out on millions

Which countries have the world’s largest coal reserves?

This New Ultralight Aircraft May Be World’s Fastest Single-Engine Business Jet